QuidelOrtho Introduces Rapid QUICKVUE Influenza + SARS Test
QuidelOrtho Introduces Innovative QUICKVUE Influenza + SARS Test
QuidelOrtho Corporation (Nasdaq: QDEL), a recognized leader in point-of-care diagnostic testing, has launched the QUICKVUE Influenza + SARS Test. This groundbreaking test is designed to provide rapid, user-friendly immunoassay for professional settings, enhancing the diagnosis of respiratory illnesses.
Understanding QUICKVUE Influenza + SARS Test
The QUICKVUE Influenza + SARS Test allows for the rapid detection and differentiation of influenza A, influenza B, and SARS-CoV-2 with just a single patient sample. With results ready in as little as 10 minutes, this innovative solution improves clinicians' ability to make timely treatment decisions, crucial during seasons when both COVID-19 and influenza circulate, presenting similar symptoms.
Distinct Features of the QUICKVUE Test
What sets the QUICKVUE test apart are its defining features:
- Triple Detection Capability: This unique feature enables healthcare providers to differentiate between influenza A, influenza B, and COVID-19 in one convenient test.
- Quick Results: Achieving results in just 10 minutes, this test is perfect for point-of-care applications where time is critical.
- Professional Use: The test is tailored for CLIA-waived settings as well as moderate and high-complexity laboratory situations.
- Streamlined Workflow: It includes an easy nasal swab collection process, optimized for efficiency and clarity in results.
- Accessible Pricing: This cost-effective testing option aims to make rapid diagnosis more affordable for healthcare facilities.
Expert Insight on NEW QUICKVUE Testing
Commenting on the launch, Dr. Tammi Ranalli, Senior Vice President, Molecular Diagnostics, and Point of Care Business Units at QuidelOrtho, expressed, "Healthcare providers, especially in physician office labs and urgent care scenarios, require reliable tools to accurately diagnose respiratory illnesses. The QUICKVUE Influenza + SARS Test equips them with an efficient option, enhancing patient care during critical times."
Expanding QuidelOrtho's Portfolio
This new addition to QuidelOrtho’s respiratory testing solutions aligns with their commitment to innovation within healthcare. The QUICKVUE test complements the SOFIA™ 2 Flu + SARS Antigen FIA by offering an alternative that is more visually driven. This ensures that medical professionals have versatile options for diagnosis, reinforcing QuidelOrtho's market leadership in point-of-care testing.
Availability of QUICKVUE Test
The QUICKVUE Influenza + SARS Test is selectively available across various distribution channels and is specifically intended for use in professional medical settings, ensuring high-quality control and accurate diagnosis.
About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) is a prominent provider of advanced diagnostic solutions. With a broad expertise encompassing clinical chemistry, immunoassay, immunohematology, and molecular testing, they are dedicated to delivering reliable results that significantly enhance patient care.
QuidelOrtho prides itself on a legacy of innovation, working closely with healthcare providers to facilitate informed decisions that improve outcomes for patients—from point-of-care to laboratory settings.
Contact Information
Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
Media Contact:
D. Nikki Wheeler
Senior Director, Corporate Communications
Frequently Asked Questions
What does the QUICKVUE Influenza + SARS Test offer?
The QUICKVUE test provides rapid detection and differentiation of influenza A, influenza B, and SARS-CoV-2 from a single sample.
How quickly can results be obtained?
Results can be obtained in as fast as 10 minutes, making it suitable for point-of-care use.
Who can use the QUICKVUE Test?
The test is designed for use by healthcare professionals in physician office laboratories, urgent care centers, and other medical facilities.
Why is this test important for respiratory illnesses?
This test helps clinicians differentiate between COVID-19 and influenza, which both present similar symptoms, facilitating timely treatment decisions.
What is QuidelOrtho known for?
QuidelOrtho is known for its innovative diagnostic solutions across various testing sectors, enhancing patient outcomes with accurate and rapid test results.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.